Press release from the extraordinary general meeting of Vicore Pharma Holding AB (publ)
At the extraordinary general meeting (the “EGM”) of Vicore Pharma Holding AB (publ) (the “Company”) held on 5 March 2021, the below resolutions were mainly passed. Due to the extraordinary situation resulting from the COVID-19 pandemic the EGM was carried out through postal voting, without physical presence.
Approval of the board of directors’ resolution to issue shares
The EGM resolved to approve the board of directors’ resolution to issue 11,200,000 shares at a subscription price of SEK 30.00 per share from 9 February 2021. The right to subscribe for the new shares shall, with deviation from the shareholders’ pre-emption rights, be granted Swedish and international institutional investors as well as certain existing shareholders, who have been identified through a so-called private placement procedure. The reasons for the deviation from the shareholders’ pre-emption rights are that the Company shall, in a timely manner, be able to secure the capital need for the Company’s operations, as well as to broaden the ownership structure of the Company with Swedish and international institutional investors.
For further information regarding the approval of the board of directors’ resolution to issue shares, please refer to the Company’s webpage www.vicorepharma.com. Minutes from the EGM will be made available at the same website no later than two weeks after the EGM.
Gothenburg, 5 March 2021
Vicore Pharma Holding AB (publ)
For further information, please contact:
Carl-Johan Dalsgaard, CEO
Phone: +46 70 975 98 63
Hans Jeppsson, CFO
Phone: +46 70 553 14 65
The information was submitted for publication through the agency of the contact persons set out above on 5 March 2021 at 11:30 CET.